Epidemiological studies found that men with BlCa treated with 5α-reductase inhibitors, which block conversion of testosterone to the more potent dihydrotestosterone, exhibited a lower risk of BlCa related death10, further supporting a role for AR in BlCa. This evidence concerns the gene AR and bladder transitional cell carcinoma.